ubald1 Antibody

What is UBALD1 and what are its key characteristics?

UBALD1 (UBA-Like Domain Containing 1), also known as FAM100A or PP11303, is a protein encoded by the UBALD1 gene located on chromosome 16p13.3 in humans . The protein has high ubiquitous tissue expression and localizes in both the nucleus and cytoplasm . UBALD1 is evolutionarily conserved across animal species, including invertebrates, suggesting important biological functions .

The human UBALD1 gene contains three exons and two introns with a total gene length of 6,145 base pairs . The protein exists in three isoforms with different properties:

Isoform 1 is the longest and contains both UBA-like and PHA03247 domains, while isoforms 2 and 3 lack the PHA03247 domain . The presence of a UBA-like domain suggests potential involvement in ubiquitin-related cellular processes.

What types of UBALD1 antibodies are currently available for research?

As of April 2025, several UBALD1 antibodies are available for research applications:

• Rabbit polyclonal antibody against UBALD1 (100-150 aa) - This antibody is produced by immunizing rabbits with a synthetic peptide derived from the 100-150 amino acid region of human UBALD1. It has been affinity-purified and is suitable for Western Blot applications with reactivity to human, mouse, and rat UBALD1 .

• Anti-UBALD1 antibody from Sigma-Aldrich - This rabbit-produced antibody has been validated through the Human Protein Atlas project for applications including immunohistochemistry .

These antibodies typically have the following characteristics:

It's important to note that these antibodies are strictly for research use only and must not be used in diagnostic or therapeutic applications .

How should I optimize Western blot protocols for UBALD1 detection?

For optimal Western blot results when using UBALD1 antibodies, follow these methodological recommendations:

Sample preparation:

• Use fresh samples with appropriate lysis buffers containing protease inhibitors

• Extract both nuclear and cytoplasmic proteins to capture all UBALD1 isoforms

• Load 20-50 μg total protein per lane

Electrophoresis and transfer:

• Use 12-15% SDS-PAGE gels to properly resolve UBALD1 (predicted MW ~19 kDa)

• Transfer using standard PVDF or nitrocellulose membranes

Blocking and antibody incubation:

• Block with 5% non-fat dry milk or BSA in TBST

• Dilute primary antibody at 1:500-1:2000 (optimize for your specific antibody)

• Incubate overnight at 4°C or 1-2 hours at room temperature

• Use HRP-conjugated secondary antibodies at appropriate dilutions

Detection and validation:

• Visualize using standard ECL systems

• Expected bands: ~19 kDa (isoform 1), ~16 kDa (isoform 2), ~13 kDa (isoform 3)

• Include positive controls (cell lines known to express UBALD1)

• Consider UBALD1 knockdown samples as negative controls

For storage, keep antibodies at -20°C for up to 1 year from receipt and avoid repeated freeze-thaw cycles .

How do chemical exposures affect UBALD1 expression and antibody detection?

Understanding chemical interactions with UBALD1 can inform experimental design when using UBALD1 antibodies. According to gene-chemical interaction data, several compounds modulate UBALD1 expression:

When using UBALD1 antibodies in experiments involving these chemicals:

• Consider timing of chemical treatments, as expression changes may be time-dependent

• Include appropriate controls to account for chemical effects on UBALD1 levels

• Validate antibody detection sensitivity under these chemical exposure conditions

• Consider correlating protein detection with mRNA analysis to confirm expression changes

This information can help researchers design appropriate controls and interpret results when studying UBALD1 in toxicological or pharmacological contexts .

What is the relationship between UBALD1 and other UBA domain-containing proteins?

UBALD1 contains a UBA-like domain that distinguishes it from other proteins in the ubiquitin pathway:

When working with UBALD1 antibodies, it's crucial to verify specificity against these related proteins. For example, the UBE1L2/UBA6 antibody (#13386) from Cell Signaling Technology specifically does not cross-react with UBE1/UBA1 or UBE1L/UBA7 proteins . Similarly, UBALD1 antibodies should be validated for lack of cross-reactivity with other UBA domain-containing proteins.

Understanding these distinctions is important when:

• Interpreting Western blot bands at similar molecular weights

• Designing co-immunoprecipitation experiments to study protein interactions

• Investigating potential functional redundancy or compensation

How can I validate the specificity of UBALD1 antibodies?

Rigorous validation is essential to ensure antibody specificity. For UBALD1 antibodies, employ these methodological approaches:

Genetic validation methods:

• siRNA/shRNA knockdown: Compare antibody signal in control vs. UBALD1-depleted samples

• CRISPR/Cas9 knockout: Generate UBALD1-null cells as definitive negative controls

• Overexpression: Express tagged UBALD1 constructs and confirm co-detection

Biochemical validation methods:

• Peptide competition: Pre-incubate antibody with immunizing peptide to block specific binding

• Immunoprecipitation-Mass Spectrometry: Confirm identity of pulled-down proteins

• Orthogonal antibodies: Compare results using antibodies targeting different UBALD1 epitopes

Specificity controls:

• Cross-reactivity testing: Verify lack of reactivity against related UBA domain proteins

• Isoform specificity: Test against samples expressing different UBALD1 isoforms

• Multiple applications: Confirm consistent results across different techniques (WB, IHC, IF)

Document all validation experiments thoroughly, as this information is critical for publication quality and reproducibility. Consider following the validation guidelines proposed by the International Working Group for Antibody Validation (IWGAV).

How do UBALD1 antibodies compare to antibodies against other ubiquitin pathway proteins?

When conducting comparative studies of ubiquitin pathway components, understanding the technical differences between antibodies is critical:

Key methodological differences when working with these antibodies:

• Sample preparation: UBA1 and UBA6 typically require less protein loading (10-20 μg) due to higher abundance

• Resolution requirements: UBALD1 requires higher percentage gels (12-15%) while UBA1/UBA6 require lower percentage gels (8-10%)

• Blocking conditions: May need optimization for each specific antibody

• Multiplexing potential: Consider using differentially labeled secondary antibodies for co-detection

• Subcellular fractionation: UBA1/UBA6 are predominantly cytoplasmic while UBALD1 is both nuclear and cytoplasmic

When designing experiments involving multiple ubiquitin pathway components, consider using specialized lysate preparation methods that maintain protein-protein interactions if studying complex formation.

How can I study UBALD1 in disease models using available antibodies?

While specific disease associations for UBALD1 are still being investigated, research into related UBA domain proteins offers methodological insights:

Neurological disease models:

• Loss of neuronal UBA6 during development causes altered patterning in the hippocampus and amygdala, with decreased dendritic spine density

• When studying UBALD1 in neuronal contexts, consider:

  • Region-specific analysis (hippocampus, amygdala)

  • Dendritic spine morphology assessment

  • Co-staining with neuronal markers (NeuN)

Inflammatory disorders:

• Somatic mutations in UBA1 cause VEXAS syndrome, characterized by vacuoles, E1 enzyme defects, X-linked inheritance, autoinflammatory manifestations, and somatic mutations

• When investigating UBALD1 in inflammatory contexts:

  • Examine lineage-specific expression patterns

  • Consider testing in myeloid vs. lymphoid cells

  • Monitor hematologic parameters in animal models

Experimental approaches:

• Immunohistochemistry: Use UBALD1 antibodies for tissue distribution studies in disease models

• Flow cytometry: Examine cell-type specific expression in blood or tissue samples

• Proximity ligation assays: Investigate protein-protein interactions in situ

• Tissue microarrays: Screen multiple disease samples simultaneously

When studying potential UBALD1 involvement in diseases associated with other UBA domain proteins, carefully validate antibody specificity in each experimental system to avoid cross-reactivity with related proteins.

What considerations are important when designing UBALD1 co-immunoprecipitation experiments?

Co-immunoprecipitation (Co-IP) experiments with UBALD1 antibodies require careful optimization:

Protocol optimization:

• Lysis conditions:

  • Use mild detergents (0.5-1% NP-40 or Triton X-100) to preserve protein interactions

  • Include protease inhibitors to prevent degradation

  • Consider phosphatase inhibitors if studying phosphorylation-dependent interactions

• Antibody selection:

  • Choose antibodies validated for IP applications

  • Consider using different antibodies for IP and detection to avoid IgG interference

  • Determine optimal antibody-to-lysate ratio (typically 2-5 μg antibody per 500-1000 μg protein)

• Binding conditions:

  • Incubate overnight at 4°C with gentle rotation

  • Use protein A/G beads appropriate for the host species of the antibody

  • Include pre-clearing steps to reduce non-specific binding

Controls and validation:

• Essential controls:

  • IgG control (same species as UBALD1 antibody)

  • Input control (5-10% of starting material)

  • Reverse Co-IP when possible (IP with antibody against interacting protein)

• Validation approaches:

  • Confirm interaction by Western blot

  • Consider mass spectrometry for unbiased interaction screening

  • Validate key interactions with orthogonal methods (proximity ligation, FRET)

For studying potential interactions of UBALD1 with ubiquitin pathway components, consider both native conditions and conditions that stabilize transient interactions (e.g., proteasome inhibition).

How can I distinguish between different UBALD1 isoforms using antibodies?

Discriminating between the three UBALD1 isoforms requires specialized approaches:

Antibody selection strategies:

• Pan-UBALD1 antibodies: Target regions common to all isoforms for total UBALD1 detection

• Isoform-specific antibodies: Use antibodies targeting unique regions:

  • Isoform 1: Target the 25 amino acids present in isoform 1 but absent in isoform 2

  • Isoform 3: Target the unique N-terminal region resulting from frameshift

Western blot optimization:

• Use high-resolution gels (15-20% or gradient gels) to separate isoforms by size:

  • Isoform 1: ~19 kDa

  • Isoform 2: ~16 kDa

  • Isoform 3: ~13 kDa

• Run longer electrophoresis times to achieve better separation

• Consider using recombinant isoform standards as positive controls

Validation approaches:

• Genetic manipulation: Create isoform-specific knockdown/knockout models

• Overexpression: Express individual isoforms with different tags

• Mass spectrometry: Identify isoform-specific peptides after immunoprecipitation

• RT-PCR correlation: Correlate protein detection with isoform-specific mRNA expression

The Human Protein Atlas project has performed extensive antibody validation, which can provide guidance for UBALD1 isoform detection .